Characterisation of LRRK2 kinase function in a-synuclein-induced neurotoxicity and neuroinflammation. KU Leuven
Parkinson’s disease (PD) is the most common neurodegenerative motor disease, affecting 10 million people worldwide. To date, PD cannot be cured, instead therapy is directed at alleviating symptoms. A major challenge is therefore the development of disease-modifying therapies which halt, or at least slow down, disease progression. Leucine-rich repeat kinase 2 (LRRK2) kinase inhibitors are currently in a preclinical stage and considered as ...